Search results for " OSTEOPOROSI"

showing 10 items of 110 documents

Fratture da fragilità, fattori di rischio clinico e comorbidità: studio retrospettivo a lungo termine

2016

Settore MED/34 - Medicina Fisica E Riabilitativariabilitazione osteoporosi fratture
researchProduct

Prevalence of Vertebral Fractures in Osteoporotic HIP Fractured Patients: The Focus Study

2015

Settore MED/34 - Medicina Fisica E Riabilitativavertebral fractures hip fractures osteoporosis rehabilitation
researchProduct

TREATMENT WITH DAILY SUBCUTANEOUS TERIPARATIDE (1-34) COMPARED WITH DAILY SUBCUTANEOUS PARATHYROID HORMONE (1-84) IN WOMEN WITH SEVERE POSTMENOPAUSAL…

2008

TERIPARATIDE PARATHYROID HORMONE OSTEOPOROSIS BONE TURNOVER BMDSettore MED/09 - Medicina Interna
researchProduct

Medication-Related Osteonecrosis of Jaws (MRONJ) Prevention and Diagnosis: Italian Consensus Update 2020

2020

The Medication-Related Osteonecrosis of Jaws (MRONJ) diagnosis process and its prevention play a role of great and rising importance, not only on the Quality of Life (QoL) of patients, but also on the decision-making process by the majority of dentists and oral surgeons involved in MRONJ prevention (primary and secondary). The present paper reports the update of the conclusions from the Consensus Conference—held at the Symposium of the Italian Society of Oral Pathology and Medicine (SIPMO) (20 October 2018, Ancona, Italy)—after the newest recommendations (2020) on MRONJ were published by two scientific societies (Italian Societies of Maxillofacial Surgery and Oral Pathology and Medicine, SI…

bisphosphonateOral SurgeonHealth Toxicology and Mutagenesislcsh:MedicineMRONJantiangiogenic agents; antiresorptive drugs; bisphosphonates; cancer; denosumab; dentistry; MRONJ; oral surgery; osteoporosis; prevention models; bisphosphonate-associated osteonecrosis of the jaw; bone density conservation agents; diphosphonates; humans; Italy; quality of life0302 clinical medicineprevention modelCancerantiangiogenic agentsdentistryBone Density Conservation AgentsDiphosphonatesConference ReportBisphosphonatesAntiresorptive DrugsDenosumabItaly030220 oncology & carcinogenesisBisphosphonate-Associated Osteonecrosis of the JawDenosumabmedicine.drugoral surgerymedicine.medical_specialtyOral surgery03 medical and health sciencesOral surgeryAntiangiogenic agentsOral and maxillofacial pathologymedicinecancerHumansantiangiogenic agentantiresorptive drugsIntensive care medicinePrevention modelsbisphosphonatesantiresorptive drugAntiangiogenic agentsbusiness.industrylcsh:RPublic Health Environmental and Occupational Healthdenosumab030206 dentistrymedicine.diseaseosteoporosisAntiresorptive drugsDentistryOsteoporosisprevention modelsbusinessAntiangiogenic agents; Antiresorptive drugs; Bisphosphonates; Cancer; Denosumab; Dentistry; MRONJ; Oral surgery; Osteoporosis; Prevention models
researchProduct

Circulating Irisin Levels as a Marker of Osteosarcopenic-Obesity in Cushing’s Disease

2020

Purpose: To evaluate circulating irisin levels in patients with active and controlled Cushing’s disease (CD). Design: Forty-four patients with CD evaluated during the active phase and after 12 months of biochemical remission and 40 controls were recruited. Methods: Phenotypic, anthropometric, hormonal and metabolic parameters, including insulin sensitivity estimation by homeostatic model of insulin resistance, Matsuda index and oral disposition index and circulating irisin levels were evaluated. Results: Patients with active CD showed lower irisin levels compared to controls (p<0.001) and controlled CD (p<0.001). The independent variables significantly associated with irisin were wais…

irisin osteoporosis myopathy Cushing’s diseaseCushing’s diseaseirisinosteoporosisSettore MED/13 - EndocrinologiaOriginal ResearchmyopathyDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy
researchProduct

Improving adherence in osteoporosis: a new management algorithm for the patient with osteoporosis

2011

Introduction: Bisphosphonates are the first-choice treatment for osteoporosis. They effectively increase bone mineral density, reduce markers of bone resorption, and lower the incidence of new fractures in patients with osteoporosis-related fracture. However, the efficacy observed in clinical trials may not be realized in a real-life setting, partly due to poor adherence to therapy, with a significant worsening of clinical outcomes. Several issues contribute to poor adherence to osteoporosis medication, including inconvenient dosing regimens and concerns about possible adverse events. Although strategies to improve adherence have been investigated, new approaches are required. Areas covered…

medicine.medical_specialtyBone Density Conservation AgentBone densityOsteoporosisAlternative medicineadherence; osteoporosis; treatment algorithm; bone density; medication possession ratio; bisphosphonatesMedication AdherenceClinical ProtocolsCost of IllnessTreatment algorithmmedicineHumansBisphosphonatePharmacology (medical)DosingClinical ProtocolAdverse effectMED/01 - STATISTICA MEDICAOsteoporosis PostmenopausalAdherence bisphosphonates bone density medication possession ratio osteoporosis treatment algorithmMedication possession ratioPharmacologyBone Density Conservation Agentsbusiness.industryOsteoporosiGeneral Medicinemedicine.diseaseAlgorithmCost of IllneClinical trialBone Density Conservation AgentsTreatment OutcomeZoledronic acidAdherenceAdherence; Bisphosphonates; Bone density; Medication possession ratio; Osteoporosis; Treatment algorithm; Algorithms; Bone Density Conservation Agents; Clinical Protocols; Cost of Illness; Female; Humans; Osteoporosis; Osteoporosis Postmenopausal; Treatment Outcome; Medication Adherence; Pharmacology; Pharmacology (medical)Physical therapyOsteoporosisFemaleBone densitybusinessAlgorithmsHumanmedicine.drugExpert Opinion on Pharmacotherapy
researchProduct

Guidelines for the management of osteoporosis and fragility fractures

2018

The purpose of this document, a result of the harmonisation and revision of Guidelines published separately by the SIMFER, SIOMMMS/SIR, and SIOT associations, is to provide practical indications based on specific levels of evidence and various grades of recommendations, drawn from available literature, for the management of osteoporosis and for the diagnosis, prevention, and treatment of fragility fractures. These indications were discussed and formally approved by the delegates of the Italian Scientific Associations involved in the project (SIE, SIGG, SIMFER, SIMG, SIMI, SIOMMMS, SIR, and SIOT). The purpose of this document, a result of the harmonisation and revision of Guidelines publishe…

medicine.medical_specialtyBone densityOsteoporosis030204 cardiovascular system & hematologyEM - Original03 medical and health sciences0302 clinical medicineFragilityBone DensitymedicineSettore MED/33 - Malattie Apparato LocomotoreInternal MedicineHumans030212 general & internal medicineFractures; Osteoporosis; Therapy; Internal Medicine; Emergency Medicinebusiness.industryOsteoporosiEvidence-based medicinemedicine.diseaseFractures; Osteoporosis; TherapyFractureItalyFamily medicineEmergency MedicineOsteoporosisTherapybusinessFracturesOsteoporotic Fractures
researchProduct

The assessment of vertebral fractures in elderly women with recent hip fractures: the BREAK Study

2012

This study aimed to evaluate the prevalence of vertebral fractures in elderly women with a recent hip fracture. The burden of vertebral fractures expressed by the Spinal Deformity Index (SDI) is more strictly associated with the trochanteric than the cervical localization of hip fracture and may influence short-term functional outcomes. INTRODUCTION: This study aimed to determine the prevalence and severity of vertebral fractures in elderly women with recent hip fracture and to assess whether the burden of vertebral fractures may be differently associated with trochanteric hip fractures with respect to cervical hip fractures. METHODS: We studied 689 Italian women aged 60 years or over with …

medicine.medical_specialtyEndocrinology Diabetes and MetabolismOsteoporosisDentistryWalkingelderlySeverity of Illness Indexvertebral fracture; hip fracture; elderly; osteoporosis; burdenThoracic VertebraeburdenHip fractureInternal medicinemedicinePrevalenceHumansLife StyleSpinal deformity indexCervical fractureTrochanteric fractureAgedAged 80 and overHip fractureLumbar VertebraeCervical fracturebusiness.industryHip FracturesSettore MED/34 - Medicina Fisica E RiabilitativaMiddle Agedmedicine.diseaseosteoporosisRheumatologyRadiographyItalyOrthopedic surgerycervical fracutre hip fracture spinal deformity index trochanteric fracture vertebral fractureSpinal deformitySpinal FracturesFemaleVertebral fracturebusinessOsteoporotic Fractures
researchProduct

Underdiagnosis and undertreatment of osteoporotic patients admitted in internal medicine wards in Italy between 2010 and 2016 (the REPOSI Register)

2021

Purpose: To evaluate clinical features, treatments, and outcomes of osteoporotic patients admitted to internal medicine and geriatric wards compared with non-osteoporotic patients (REPOSI registry). Methods: We studied 4714 patients hospitalized between 2010 and 2016. We reported age, sex, educational level, living status, comorbidities and drugs taken, Cumulative Illness Rating Scale (CIRS), Barthel Index, Short-Blessed Test, 4-item Geriatric Depression Scale, serum hemoglobin, creatinine, and clinical outcomes. Osteoporosis was defined based on the diagnoses recorded at admission, according to the following ICD9: 733, 805-813, 820-823. Results: Twelve percent of the patients had a preadmi…

medicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosis030209 endocrinology & metabolismNO03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyRating scaleInternal medicineDiabetes mellitusVitamin D and neurologyInternal MedicineMedicineeracturesHumansBisphosphonateMedical diagnosisbisphosphonates; eractures; osteoporosis; vitamin DVitamin DAgedCreatinineRehabilitationLS7_9Bisphosphonates; Fractures; Osteoporosis; Vitamin D.business.industryOsteoporosiBisphosphonatesmedicine.diseaseHospitalizationFracturechemistryItaly030220 oncology & carcinogenesisOsteoporosisGeriatric Depression ScaleVitamin D.businessBisphosphonates; Fractures; Osteoporosis; Vitamin D; Aged; Hospitalization; Humans; Internal Medicine; Italy; Vitamin D; OsteoporosisBisphosphonates; Fractures; Osteoporosis; Vitamin DFractures
researchProduct

Fracture incidence and characterization in patients on osteoporosis treatment: The ICARO study

2006

None of the available osteoporosis therapies have been shown to completely abolish the risk of fractures. In clinical practice, the outcome may be even poorer. In 880 patients prescribed with antiresorptives (alendronate, risedronate, and raloxifene) for >1 year, a fragility fracture was recorded in 8.9%/year of them. This incidence is considerably higher than that observed in randomized clinical trials, and it was significantly related to poor compliance and lack of supplementation with calcium and vitamin D. Introduction: Osteoporotic fracture is one of the most important public health concerns among the elderly. Currently available therapies have been shown to significantly decrease the …

medicine.medical_specialtyFracture riskEndocrinology Diabetes and MetabolismOsteoporosisIncidence; FRACTURETreatment resistancelaw.inventionCalcium and vitamin D intake Fracture risk Osteoporosis Treatment compliance Treatment resistancecalcium and vitamin d intake; fracture risk; osteoporosis; treatment compliance; treatment resistanceFractures BoneRandomized controlled trialRisk FactorslawInternal medicineCalcium and vitamin D intakemedicineVitamin D and neurologyHumansOrthopedics and Sports MedicineRaloxifeneVitamin DAgedRetrospective StudiesAlendronateBone Density Conservation Agentsbusiness.industryIncidenceIncidence (epidemiology)Etidronic AcidRetrospective cohort studyMiddle Agedmedicine.diseaseCalcium and vitamin D intake Fracture incidence Fracture risk Osteoporosis Treatment compliance Treatment resistanceFRACTUREFracture incidenceSurgeryItalyRaloxifene HydrochlorideRisedronic acidOsteoporosisFemaleObservational studyTreatment compliancebusinessRisedronic Acidmedicine.drug
researchProduct